Meeting
2018 ASCO Annual Meeting
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).
Authors
Ari M. Vanderwalde
Division of Hematology/Oncology, The University of Tennessee Health Science Center, West Cancer Center, Germantown, TN
Ari M. Vanderwalde , Michaella Latkovic-Taber , Siwen Hu-Lieskovan , Kenneth F. Grossmann , Jeffrey Alan Sosman , Danae Campos , Michael Wu , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03033576
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9597)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9597
Abstract #
TPS9597
Poster Bd #
423a
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.
First Author: Mark Selby
Poster
2013 ASCO Annual Meeting
An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
First Author: F. Stephen Hodi
Poster
2013 ASCO Annual Meeting
Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models.
First Author: Maria Jure-Kunkel
Poster
2013 ASCO Annual Meeting
An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).
First Author: Jeffrey Alan Sosman